Obsessive-Compulsive Disorder (OCD) Cell Models for Research

Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition characterized by intrusive thoughts (obsessions) and repetitive behaviors (compulsions). According to the World Health Organization (WHO), OCD affects approximately 2-3% of the global population, with a lifetime prevalence of about 2.3%. It is among the top 10 causes of disability worldwide, with significant impacts on quality of life and socioeconomic burden. Onset typically occurs in adolescence or early adulthood, and the disorder is often underdiagnosed and undertreated. The National Institute of Mental Health (NIMH) reports that OCD has a heritability of about 40-50%, indicating a strong genetic component. The clinical impact is profound, with many patients experiencing chronic symptoms that impair daily functioning. Research into the molecular mechanisms of OCD is critical for developing targeted therapies and improving patient outcomes.

OCD is an ideal model for mechanistic studies due to its well-defined neurocircuitry, particularly the cortico-striato-thalamo-cortical (CSTC) loop. The disorder has a clear genetic basis, with multiple susceptibility genes identified, including SLC1A1, GRIN2B, and DLGAP3. Public datasets, such as the Psychiatric Genomics Consortium (PGC) and the NIMH Repository and Genomics Resource, provide extensive genetic and phenotypic data. Open questions include the precise role of glutamate signaling, synaptic plasticity, and immune dysregulation. Gene-edited cell models offer a powerful approach to dissect these pathways and validate potential drug targets.

While OCD is not a cancer, the term 'pathogenesis' is used here to describe the molecular mechanisms underlying the disorder. The major pathways implicated in OCD include:

• • Glutamatergic signaling: Dysregulation of glutamate neurotransmission in the CSTC loop is a key feature. Genes such as SLC1A1 (encoding the excitatory amino acid transporter EAAT3) and GRIN2B (encoding the NMDA receptor subunit GluN2B) are involved.
• • Serotonergic signaling: The serotonin transporter (SLC6A4) and serotonin receptors (HTR2A) are targets of first-line treatments (SSRIs), indicating their role in symptom modulation.
• • Dopaminergic signaling: Dopamine D2 receptor (DRD2) and catechol-O-methyltransferase (COMT) are implicated in the modulation of compulsions.
• • Synaptic plasticity and neurotrophins: Brain-derived neurotrophic factor (BDNF) and its receptor TrkB (NTRK2) are involved in synaptic plasticity and neuronal survival, with altered expression in OCD.
• • Immune and inflammatory pathways: Elevated levels of pro-inflammatory cytokines (e.g., TNF-α, IL-6) have been observed in OCD patients, suggesting a role for neuroinflammation.

Data from PGC, ClinVar, and COSMIC.

The deregulated signaling networks in OCD include:

• • Glutamatergic network: Key nodes include EAAT3 (SLC1A1), NMDA receptors (GRIN1, GRIN2A, GRIN2B), and metabotropic glutamate receptors (GRM5). Altered glutamate levels lead to excitotoxicity and synaptic dysfunction.
• • Serotonergic network: Serotonin transporter (SLC6A4), 5-HT1A (HTR1A), and 5-HT2A (HTR2A) receptors. Dysregulation affects mood and anxiety circuits.
• • Dopaminergic network: Dopamine D1 (DRD1) and D2 (DRD2) receptors, COMT, and monoamine oxidase A (MAOA). Imbalance in dopamine signaling contributes to compulsive behaviors.
• • Neurotrophin signaling: BDNF and NTRK2 (TrkB) activate PI3K/AKT and MAPK pathways, promoting neuronal survival and plasticity. Altered BDNF levels are linked to OCD.
• • Immune signaling: Cytokine receptors (TNFRSF1A, IL6R) activate NF-κB and JAK/STAT pathways, leading to neuroinflammation and oxidative stress.

Organoids derived from induced pluripotent stem cells (iPSCs) offer a more physiologically relevant model, recapitulating cortical and striatal development. They can be generated from OCD patients to study disease-specific phenotypes.

• • PDX (Patient-Derived Xenograft): Not applicable for OCD as it is not a cancer; however, patient-derived iPSC-derived neurons can be transplanted into mouse brains to study human-specific mechanisms.
• • GEMM (Genetically Engineered Mouse Models): Examples include:
• • SLC1A1 knockout mice: Show increased anxiety-like and compulsive behaviors.
• • GRIN2B conditional knockout mice: Exhibit altered glutamatergic signaling and repetitive behaviors.
• • DLGAP3 knockout mice: Display compulsive grooming and increased glutamate levels.
• • Induced models: Pharmacological models using 8-OH-DPAT (5-HT1A agonist) or MK-801 (NMDA antagonist) to induce OCD-like behaviors in rodents.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts (KO) or knock-ins (KI) of OCD-associated genes. For example:

• • SLC1A1 knockout SH-SY5Y cells: Model glutamate transporter deficiency, allowing study of synaptic glutamate accumulation and downstream signaling.
• • GRIN2B knock-in cells with a pathogenic variant (e.g., p.Val607Ile): Mimic enhanced NMDA receptor activity, useful for testing antagonists.
• • SLC6A4 knockout cells: Model serotonin transporter loss, relevant to SSRI response.

These sequence-verified, commercially available models provide a controlled system to investigate molecular pathways and screen potential therapeutics. They are essential for drug discovery and functional genomics, offering reproducibility and scalability.

Knockout and knock-in lines are used to validate the functional significance of OCD-associated genes. For example, SLC1A1 knockout cells show increased extracellular glutamate and altered expression of NMDA receptor subunits, confirming its role in glutamatergic signaling. Similarly, GRIN2B knock-in cells exhibit enhanced calcium influx upon NMDA stimulation, validating the gain-of-function effect. These models allow researchers to study gene function in a controlled environment, complementing animal studies.

Isogenic pairs (wild-type vs. knockout) are ideal for high-throughput screening of compounds that modulate specific pathways. For instance, screening for compounds that reduce glutamate release in SLC1A1 KO cells could identify novel therapeutic candidates. Additionally, drug resistance can be modeled by exposing cells to SSRIs and selecting resistant clones, then analyzing genetic and epigenetic changes. Gene-edited cells provide a consistent platform for such assays.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in the context of an OCD-associated mutation. For example, in GRIN2B mutant cells, knocking out a gene involved in calcium homeostasis might be lethal, revealing potential drug targets. Gene-edited cells also facilitate the identification of biomarkers by comparing protein expression and secretion profiles between mutant and wild-type lines.